BioNTech has initiated a Phase III clinical trial for its oncology candidate BNT324 in metastatic castration-resistant prostate cancer, aiming to compare the drug against current standard chemotherapy ...

Prostate cancer (PCa) is one of the most common malignant tumors among men worldwide. Following androgen deprivation therapy ...

NCI-Led Study Shows Median PFS of 9.6 Months Results Presented at AACR Special Conference on Innovations in Prostate CancerPRINCETON, N.J., Jan.

SGLT2 inhibitors linked to lower hormone therapy failure in prostate cancer. Learn more about their potential role in improving treatment outcomes.

This article summarizes metabolic reprogramming in prostate cancer (PCa). Early PCa relies more on glycolysis.

SAN FRANCISCO, September 28, 2025 — A new clinical trial finds that people with a limited number of metastases from recurrent prostate cancer lived significantly longer without disease progression ...

A new drug combination could significantly delay the progression of a life-threatening form of prostate cancer in men with specific genetic mutations, finds a major international trial led by UCL ...

University Hospitals Seidman Cancer Center researchers have developed a tool that could identify metastatic prostate cancer ...

Add Yahoo as a preferred source to see more of our stories on Google. For men facing the return of prostate cancer, a new combination therapy may offer a much longer break before the disease comes ...

In a statement, NICE said the new guidance for Talzenna will make it an option for around 2,400 people in England and reduce ...